HB1809
Passed House, In Senate(New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.
Status
Hearing
No upcoming hearing scheduled.
Testimony
51 total submissions
Bill Docket
Introduced 03/26/2026 and Referred to Health and Human Services; SJ 7
SenateMarch 30, 2026
Ought to Pass with Amendment 2026-1201h: MA VV 03/26/2026 HJ 9
HouseMarch 26, 2026
Amendment # 2026-1201h (NT): AA DV 248-101 03/26/2026 HJ 9
HouseMarch 26, 2026
Inexpedient to Legislate: MF DV 127-222 03/26/2026 HJ 9
HouseMarch 26, 2026
Minority Committee Report: Ought to Pass with Amendment # 2026-1201h (NT)
HouseMarch 19, 2026
Majority Committee Report: Inexpedient to Legislate 03/17/2026 (Vote 13-11; RC)
HouseMarch 19, 2026
Executive Session: 03/17/2026 10:00 am GP 230
HouseMarch 13, 2026
Division III Work Session: 03/13/2026 09:00 am GP 234
HouseMarch 09, 2026
Referred to Finance 02/12/2026 HJ 4
HouseFebruary 12, 2026
Ought to Pass: MA VV 02/12/2026 HJ 4
HouseFebruary 12, 2026
Committee Report: Ought to Pass 01/28/2026 (Vote 18-0; CC) HC 6 P. 7
HouseFebruary 03, 2026
Executive Session: 01/28/2026 02:30 pm GP 158
HouseJanuary 21, 2026
Public Hearing: 01/14/2026 03:00 pm GP 158
HouseJanuary 08, 2026
Introduced 01/07/2026 and referred to Health, Human Services and Elderly Affairs HJ 1 P. 37
HouseDecember 18, 2025